In the wake of the increase in Current Liabilities in the fourth quarter 2025, Quick Ratio fell to 0.28 below Strata Skin Sciences Inc average.

Within Medical Equipment & Supplies industry 173 other companies have achieved higher Quick Ratio than Strata Skin Sciences Inc in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 2025 to 3365.

Explain Quick Ratio?
How much Cash & cash equivalents SSKN�s has?
What are SSKN�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

SSKN Quick Ratio	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2	(Mar 31 2025) Q1	(Dec 31 2024) Q4
Y / Y Current Liabilities Change	51.14 %	14.19 %	11.06 %	15.61 %	200.41 %
Y / Y Cash & cash equivalent Change	8.97 %	0.2 %	8.81 %	24.35 %	7.03 %
Quick Ratio MRQ	0.28	0.47	0.48	0.48	0.39
SSKN's Total Ranking	# 3365	# 2025	# 2129	# 2337	# 2142
Seq. Current Liabilities Change	86.38 %	19.78 %	-7.71 %	-26.64 %	40.81 %
Seq. Cash & cash equivalent Change	11.81 %	18.61 %	-8.38 %	-10.32 %	2.82 %

Quick Ratio fourth quarter 2025 Company Ranking
Within:	No.
Medical Equipment & Supplies Industry	# 174
Healthcare Sector	# 864
Overall Market	# 3365

Quick Ratio Statistics
High	Average	Low
19.34	1.93	0.21
(Dec 31 2011)		(Sep 30 2015)

Financial Statements
Strata Skin Sciences Inc's Current Liabilities	$ 28 Millions	Visit SSKN's Balance sheet
Strata Skin Sciences Inc's Cash & cash equivalent	$ 8 Millions	Visit SSKN's Balance sheet
Source of SSKN's Sales		Visit SSKN's Sales by Geography

Cumulative Strata Skin Sciences Inc's Quick Ratio

SSKN's Quick Ratio for the trailling 12 Months

SSKN Quick Ratio	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months	(Mar 31 2025) 12 Months	(Dec 31 2024) 12 Months
Y / Y Current Liabilities TTM Growth	26.36 %	40.85 %	62.79 %	77.46 %	103.82 %
Y / Y Cash & cash equivalent TTM Growth	9.68 %	9.15 %	8.79 %	-6.63 %	-2.84 %
Quick Ratio TTM	0.4	0.45	0.46	0.46	0.46
Total Ranking TTM	# 4081	# 3051	# 3109	# 2432	# 3398
Seq. Current Liabilities TTM Growth	15.88 %	3.23 %	2.21 %	3.35 %	29.17 %
Seq. Cash & cash equivalent TTM Growth	2.43 %	0.05 %	1.84 %	5.09 %	1.94 %

Quick ratio ranking by company, industry and sector >> Back to SSKN Financial Strength Comparisons >> Go to Compare SSKN Quick Ratio to its Competitors

On the trailing twelve months basis Due to jump in Current Liabilities in the Q4 2025 to $28.02 millions, cumulative Quick Ratio decreased to 0.4 below the Strata Skin Sciences Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Equipment & Supplies industry 208 other companies have achieved higher Quick Ratio than Strata Skin Sciences Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 3051 to 4081.

Explain Quick Ratio?
How much Cash & cash equivalents SSKN�s has?
What are SSKN�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Equipment & Supplies Industry	# 209
Healthcare Sector	# 991
Within the Market	# 4081

trailing twelve months Quick Ratio Statistics
High	Average	Low
4.06	0.97	0.35
(Sep 30 2013)		(Mar 31 2016)

Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Medical Equipment & Supplies Industry	Quick Ratio	Dec 31 2025 MRQ Cash & cash equivalent	Dec 31 2025 MRQ Current Liabilities
Docgo Inc	0.76	$ 51.019 Millions	$ 67.490 Millions
Angiodynamics Inc	0.73	$ 55.893 Millions	$ 76.197 Millions
Medtronic Plc	0.70	$ 8,965.000 Millions	$ 12,879.000 Millions
Streamex Corp	0.68	$ 30.022 Millions	$ 44.217 Millions
Baxter International Inc	0.66	$ 1,966.000 Millions	$ 2,970.000 Millions
Cytosorbents Corporation	0.64	$ 6.249 Millions	$ 9.709 Millions
Innovage Holding Corp	0.64	$ 105.904 Millions	$ 164.807 Millions
Artivion Inc	0.64	$ 64.908 Millions	$ 101.556 Millions
Avita Medical Inc	0.62	$ 39.142 Millions	$ 62.677 Millions
Pro dex Inc	0.62	$ 7.159 Millions	$ 11.520 Millions
Nyxoah Sa	0.61	$ 33.601 Millions	$ 54.833 Millions
Lensar Inc	0.61	$ 17.978 Millions	$ 29.348 Millions
Stereotaxis Inc	0.60	$ 13.421 Millions	$ 22.360 Millions
Integra Lifesciences Holdings Corp	0.58	$ 263.741 Millions	$ 455.981 Millions
Avanos Medical Inc	0.57	$ 89.800 Millions	$ 157.000 Millions
Msa Safety Inc	0.57	$ 165.067 Millions	$ 289.211 Millions
Anteris Technologies Global Corp	0.57	$ 6.697 Millions	$ 11.822 Millions
Solventum Corporation	0.56	$ 878.000 Millions	$ 1,563.000 Millions
Align Technology inc	0.55	$ 1,094.908 Millions	$ 2,005.558 Millions
U S Physical Therapy Inc	0.53	$ 35.570 Millions	$ 66.654 Millions
Haemonetics Corporation	0.53	$ 306.763 Millions	$ 578.113 Millions
Teleflex Incorporated	0.50	$ 378.564 Millions	$ 762.026 Millions
Interpace Biosciences Inc	0.49	$ 2.505 Millions	$ 5.103 Millions
Sanuwave Health Inc	0.45	$ 11.959 Millions	$ 26.652 Millions
Orthofix Medical Inc	0.44	$ 82.025 Millions	$ 186.329 Millions
Dexcom Inc	0.43	$ 917.700 Millions	$ 2,129.800 Millions
Nuo Therapeutics Inc	0.42	$ 0.549 Millions	$ 1.306 Millions
Iridex Corp	0.41	$ 6.028 Millions	$ 14.608 Millions
Nuwellis Inc	0.40	$ 1.085 Millions	$ 2.686 Millions
Picard Medical Inc	0.40	$ 7.451 Millions	$ 18.695 Millions

Date modified: 2026-08-29T07:54:02+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.